The Medical Letter on Drugs and Therapeutics
Ferric Citrate (Auryxia) for Hyperphosphatemia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved ferric citrate (Auryxia – Keryx), an oral phosphate binder, for treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. It is the second iron-based phosphate binder to be approved in the US, and the first that causes significant systemic absorption of iron. Auryxia is not FDA-approved for treatment of iron deficiency anemia.

STANDARD TREATMENT — Dialysis treatment and limitation of elemental phosphate intake (typically to 750-1000 mg/day) are somewhat effective in lowering serum phosphorus levels, but addition of an oral phosphate binder is often needed. Whether phosphate-binding drugs can improve clinical outcomes has not been established.

Calcium-based phosphate binders such as calcium acetate (PhosLo, and others) are effective in reducing serum phosphate levels, but they can cause adverse gastrointestinal effects ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Ferric Citrate (Auryxia) for Hyperphosphatemia
Article code: 1483d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian